Citi lowered the firm’s price target on Edwards Lifesciences to $94 from $110 and keeps a Buy rating on the shares. The analyst also opened a “90-day negative catalyst watch” on the shares heading into the Q3 print. The firm anticipates “competitive noise” at TCT, more difficult compares in the the second half of 2023 versus 2022, and “cooled investor sentiment” on the the company’s TAVR market potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences (EW) Under the Radar of EU Antitrust Regulators
- Edwards tells Reuters cooperating with EU antitrust regulators after raid
- DraftKings upgraded, Snap initiated at Sell: Wall Street’s top analyst calls
- Early notable gainers among liquid option names on September 26th
- Edwards Lifesciences targeted in EU antitrust raid, Reuters reports